Tourmaline Bio Inc. (TRML)

NASDAQ: TRML · Real-Time Price · USD

16.18

-1.67 (-9.36%)

At close: May 02, 2025, 12:05 PM

-9.36% (1D)

Bid	16.15
Market Cap	415.58M
Revenue (ttm)	40K
Net Income (ttm)	-73.21M
EPS (ttm)	-2.89
PE Ratio (ttm)	-5.6
Forward PE	-3.56
Analyst	Buy

Ask	16.26
Volume	238,721
Avg. Volume (20D)	352,419
Open	17.74
Previous Close	17.85
Day's Range	16.02 - 18.05
52-Week Range	11.56 - 29.79
Beta	2.13

About TRML

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York....

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date May 7, 2021

Employees 74

Stock Exchange NASDAQ

Ticker Symbol TRML

Website https://www.tourmalinebio.com

Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for TRML stock is "Buy." The 12-month stock price forecast is $50, which is an increase of 209.02% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

+10.33%

Tourmaline Bio shares are trading higher on possib... Unlock content with Pro Subscription

1 month ago

+11.09%

Tourmaline Bio shares are trading higher after Wedbush initiated coverage on the stock with an Outperform rating and announced a price target of $42.

News

6 months ago · seekingalpha.com

Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting